前列腺神经内分泌恶性肿瘤全身在体分子成像的PET示踪剂选择综述
本综述从临床、生物学和分子成像角度总结[18F]FDG、放射性标记生长抑素类似物及PSMA配体在前列腺神经内分泌恶性肿瘤中的应用。结论认为治疗诱导的神经内分泌分化中PSMA表达可能较低,应优先选用[18F]FDG或生长抑素类似物;原发神经内分泌分化腺癌支持PSMA配体更优;原发神经内分泌肿瘤中高级别癌推荐[18F]FDG,高分化肿瘤推荐生长抑素类似物。
要点
- 治疗诱导神经内分泌分化者,PET-CT应选[18F]FDG或生长抑素类似物而非PSMA配体。
- 新发前列腺癌伴神经内分泌特征时,区分腺癌与原发神经内分泌恶性肿瘤对选示踪剂至关重要。
- 原发高级别神经内分泌癌用[18F]FDG,高分化神经内分泌瘤用生长抑素类似物。
关键影像表现/征象
- 治疗诱导的神经内分泌分化中PSMA表达可能较低。
- 原发神经内分泌分化腺癌中放射性标记PSMA配体成像可能更优。
- 原发高级别神经内分泌癌适合[18F]FDG成像,高分化神经内分泌瘤适合生长抑素类似物成像。
临床应用与阅片要点
- 治疗诱导神经内分泌分化者应选用[18F]FDG或生长抑素类似物PET,避免PSMA配体。
- 新发前列腺癌伴神经内分泌特征时,需鉴别腺癌与原发神经内分泌恶性肿瘤以指导示踪剂选择和临床管理。
- 原发神经内分泌肿瘤根据分化程度选择示踪剂:高级别用[18F]FDG,高分化用生长抑素类似物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Prostatic neuroendocrine malignancies represent a spectrum of diseases. Treatment-induced neuroendocrine differentiation (tiNED) in hormonally treated adenocarcinoma has been the subject of a large amount of recent research. However, the identification of neuroendocrine features in treatment-naïve prostatic tumor raises a differential diagnosis between prostatic adenocarcinoma with de novo neuroendocrine differentiation (dNED) versus one of the primary prostatic neuroendocrine tumors (P-NETs) and carcinomas (P-NECs). While [18F]FDG is being used as the main PET radiotracer in oncologic imaging and reflects cellular glucose metabolism, other molecules labeled with positron-emitting isotopes, mainly somatostatin-analogues labeled with 68Ga and prostate-specific membrane antigen (PSMA)-ligands labeled with either 18F or 68Ga, are now routinely used in departments of nuclear medicine and molecular imaging, and may be advantageous in imaging prostatic neuroendocrine malignancies. Still, the selection of the preferred PET radiotracer in such cases might be challenging. In the current review, we summarize and discuss published data on these different entities from clinical, biological, and molecular imaging standpoints. Specifically, we review the roles that [18F]FDG, radiolabeled somatostatin-analogues, and radiolabeled PSMA-ligands play in these entities in order to provide the reader with practical recommendations regarding the preferred PET radiotracers for imaging each entity. In cases of tiNED, we conclude that PSMA expression may be low and that [18F]FDG or radiolabeled somatostatin-analogues should be preferred for imaging. In cases of prostatic adenocarcinoma with dNED, we present data that support the superiority of radiolabeled PSMA-ligands. In cases of primary neuroendocrine malignancies, the use of [18F]FDG for imaging high-grade P-NECs and radiolabeled somatostatin-analogues for imaging well-differentiated P-NETs is recommended. KEY POINTS: • The preferred PET radiotracer for imaging prostatic neuroendocrine malignancies depends on the specific clinical scenario and pathologic data. • When neuroendocrine features result from hormonal therapy for prostate cancer, PET-CT should be performed with [18F]FDG or radiolabeled somatostatin-analogue rather than with radiolabeled PSMA-ligand. • When neuroendocrine features are evident in newly diagnosed prostate cancer, differentiating adenocarcinoma from primary neuroendocrine malignancy is challenging but crucial for selection of PET radiotracer and for clinical management.
引用
- Cohen, Hazut Krauthammer, Fahoum, et al. PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies. Eur Radiol. 2023. PMID: 37052659. doi:10.1007/s00330-023-09619-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。